Certain cancer cells, such as drug-tolerant persister cancer cells or therapy-resistant high-mesenchymal ones, are highly dependent on GPX4 activity, thereby exposing potential vulnerabilities for therapeutic targeting (Ran et al., 2007; Hangauer et al., 2017; Viswanathan et al., 2017). This evidence concerns the gene GPX4 and cancer.